pISSN 2234-3806eISSN 2234-3814
Table. 3.
Application of multiple-hit TP53 mutation criteria in patients with TP53 mutations according to the 5th WHO classification and ICC
| Multi-hit TP53 mutation | 5th WHO | ICC | ICC | 5th WHO/ICC | P (B vs. C) |
P (A vs. D) |
|||
|---|---|---|---|---|---|---|---|---|---|
| A: MDS (blasts<20%) (N=116) |
B: MDS (blasts<10%) (N=88) |
C: MDS/AML (10%≤blasts<20%) (N=28) |
D: AML (blasts≥20%) (N=194) |
||||||
| Criteria for multi-hit TP53 mutation | |||||||||
| 1. 5th WHO: two or more TP53 mutations | 9/116 (7.8%) | 7/88 (8.0%) | 2/28 (7.1%) | 22/194 (11.3%) | 1.000 | 0.309 | |||
| 2. 5th WHO: one TP53 mutation with 17p loss | 32/115 (27.8%) | 18/87 (20.7%) | 14/28 (50.0%) | 75/188 (39.9%) | 0.003 | 0.033 | |||
| 3. 5th WHO/ICC: one TP53 mutation with VAF >50% | 48/116 (41.4%) | 36/88 (40.9%) | 12/28 (42.9%) | 83/194 (42.8%) | 0.855 | 0.809 | |||
| 4. ICC: two or more TP53 mutations (each with a VAF >10%) | 8/116 (6.9%) | 6/88 (6.8%) | 2/28 (7.1%) | 17/194 (8.8%) | 1.000 | 0.559 | |||
| 5. ICC: one TP53 mutation (with a VAF >10%) with 17p loss | 31/115 (27.0%) | 18/87 (20.7%) | 13/28 (46.4%) | 71/188 (37.8%) | 0.008 | 0.053 | |||
| 6. ICC: one TP53 mutation (with a VAF >10%) with CK | 85/113 (75.2%) | 63/85 (74.1%) | 22/28 (78.6%) | 143/188 (76.1%) | 0.636 | 0.869 | |||
| Multi-hit TP53 mutation, N (%) according to the 5th WHO 2022 classification |
68/116 (58.6%) | 49/88 (55.7%) | 19/28 (67.9%) | 134/194 (69.1%) | 0.255 | 0.062 | |||
| Multi-hit TP53 mutation, N (%) according to the ICC |
89/116 (76.7%) | 66/88 (75.0%) | 23/28 (82.1%) | 156/194 (80.4%) | 0.436 | 0.44 | |||
| Multi-hit TP53 mutation (excluding CK), N (%) according to the ICC |
66/116 (56.9%) | 48/88 (54.5%) | 18/28 (64.3%) | 127/194 (65.5%) | 0.365 | 0.132 | |||
| Any TP53 mutation with VAF >10% | 107/116 (92.2%) | 80/88 (90.9%) | 27/28 (96.4%) | 174/194 (89.7%) | 0.685 | 0.455 |
*Corresponding to criteria 1, 2, or 3 for multi-hit TP53 mutations.
†Corresponding to criteria 3, 4, 5, or 6 for multi-hit TP53 mutations.
‡Corresponding to criteria 3, 4, or 5 for multi-hit TP53 mutations.
Bold indicates cases that meet the multi-hit criteria for TP53-mutated MDS, MDS/AML, and AML according to the 5th WHO classification and ICC.
Abbreviations: MDS, myelodysplastic neoplasm; ICC, International Consensus Classification; VAF, variant allele frequency; CK, complex karyotype.
Ann Lab Med 2025;45:160~169 https://doi.org/10.3343/alm.2024.0351
© Ann Lab Med